Vagus nerve tumours are rare growths that develop along or within the vagus nerve, most commonly in its cervical segment between the skull base and the carotid bifurcation. Because the vagus nerve controls heart rate, digestion, voice, and swallowing, tumours in this location can produce a distinctive constellation of symptoms — but many grow slowly and remain asymptomatic for years before incidental discovery on imaging.
Types of Vagus Nerve Tumours
Schwannomas are the most common vagal tumours. They arise from Schwann cells — the cells that produce the myelin sheath around nerve fibres. Vagal schwannomas are almost always benign, encapsulated, and slow-growing. They typically present as a painless neck mass that displaces the vagus nerve to one side rather than infiltrating it. This matters surgically, because the nerve can sometimes be separated from the tumour and preserved. Schwannomas account for approximately 5% of all parapharyngeal space tumours.
Paragangliomas (also called glomus vagale tumours) arise from paraganglia — clusters of neuroendocrine cells — along the vagus nerve. These are the second most common vagal tumours. Approximately 5-10% are functionally active, meaning they secrete catecholamines and can cause hypertension, palpitations, and flushing. Paragangliomas are vascular tumours that characteristically show intense enhancement on contrast MRI (the “salt and pepper” pattern) and carry a small but real malignancy risk (approximately 5-10%). About 10% of paragangliomas are hereditary, associated with mutations in succinate dehydrogenase (SDH) genes — SDH-B mutations carry the highest malignancy risk.
Neurofibromas arise from a mix of nerve cell types and grow within the nerve fascicles rather than displacing them. This makes surgical removal without sacrificing the nerve extremely difficult. Neurofibromas are associated with neurofibromatosis type 1 (NF1), and patients with NF1 may develop multiple neurofibromas along several cranial and peripheral nerves simultaneously. Unlike schwannomas, neurofibromas carry a small risk of malignant transformation (estimated 8-13% lifetime risk in NF1).
Symptoms
Symptoms depend on tumour location, size, and which vagal branches are affected.
Neck mass. The most common presentation is a painless, slow-growing mass in the lateral neck, deep to the sternocleidomastoid muscle. Many vagal tumours are discovered incidentally during imaging for unrelated reasons.
Hoarseness. Vocal cord paresis or paralysis from compression or infiltration of the recurrent laryngeal nerve or vagal motor fibres is the most specific symptom pointing to vagal origin. Hoarseness that develops gradually over weeks to months alongside a palpable neck mass warrants urgent investigation.
Dysphagia. Difficulty swallowing can occur when larger tumours compress the pharynx or oesophagus, or when vagal motor branches to the pharyngeal muscles are affected.
Autonomic symptoms. Functional paragangliomas can cause episodic hypertension, headache, palpitations, and sweating — a clinical picture mimicking phaeochromocytoma. All patients with suspected vagal paragangliomas should have 24-hour urine catecholamines and metanephrines measured before any biopsy or surgery.
Horner syndrome. Large tumours in the carotid sheath can compress the sympathetic chain, producing ptosis, miosis, and anhidrosis on the affected side.
Cranial nerve deficits. Tumours near the jugular foramen can affect adjacent cranial nerves IX (glossopharyngeal), XI (accessory), and XII (hypoglossal), producing additional swallowing difficulty, shoulder weakness, and tongue deviation.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Diagnosis
MRI with contrast is the primary imaging modality. It defines the tumour’s relationship to the vagus nerve and surrounding structures. Schwannomas typically appear as well-circumscribed, homogeneously enhancing masses. Paragangliomas show the characteristic “salt and pepper” signal on T1-weighted images due to their vascularity and flow voids.
CT angiography is useful for paragangliomas to map feeding vessels and assess vascularity before surgery. It also helps evaluate the carotid artery’s relationship to the tumour — critical for surgical planning.
Functional imaging with Gallium-68 DOTATATE PET/CT has become the gold standard for paragangliomas (2023 consensus guidelines). It detects multicentric paragangliomas (present in 10-40% of hereditary cases) and identifies metastatic disease with superior sensitivity to conventional imaging.
Genetic testing should be offered to all patients with paragangliomas. SDH subunit mutations (SDHB, SDHC, SDHD) are found in approximately 30-40% of apparently sporadic head and neck paragangliomas, and results influence surveillance strategy and family screening.
Biopsy is generally avoided for suspected paragangliomas due to vascularity and bleeding risk. The diagnosis is typically made on imaging characteristics combined with biochemical testing.
Treatment
Observation is appropriate for small, asymptomatic tumours — particularly schwannomas — in older patients or when surgical risk is high. Serial MRI monitoring (typically annual initially, then every 2-3 years if stable) can confirm slow or absent growth.
Surgery remains the definitive treatment for symptomatic or growing tumours. For schwannomas, the goal is complete excision with nerve preservation when possible. Intracapsular enucleation (shelling out the tumour from within its capsule) can preserve vagal function in 30-50% of cases, compared to near-certain vagal sacrifice with extracapsular excision. For paragangliomas, surgical planning must account for vascularity — preoperative embolisation 24-48 hours before surgery reduces intraoperative bleeding.
Vagal sacrifice during surgery produces ipsilateral vocal cord paralysis (hoarseness, breathy voice), reduced cough effectiveness, and potential swallowing difficulty. Contralateral vocal cord compensation typically improves voice quality over 6-12 months, and speech therapy with vocal cord medialization procedures can accelerate recovery.
Stereotactic radiosurgery (Gamma Knife or CyberKnife) has emerged as an alternative for paragangliomas, particularly in patients with bilateral tumours or significant surgical risk. Long-term data show tumour control rates exceeding 90% at 10 years, with preservation of existing nerve function in most cases. Radiosurgery does not remove the tumour but arrests its growth.
Systemic therapy is reserved for the rare malignant paragangliomas with metastatic disease. Options include temozolomide-based chemotherapy and peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE for somatostatin receptor-positive tumours — a treatment that has shown promising results in recent trials.
Prognosis
Most vagal schwannomas are benign and cured by complete excision. Paragangliomas have an excellent prognosis when benign (the majority), with very low recurrence rates after complete surgical removal or tumour control with radiosurgery. The main morbidity is from treatment itself — particularly vagal sacrifice and the resulting vocal cord paralysis. For hereditary paragangliomas, lifelong surveillance is necessary due to the risk of multicentric tumours developing over time.
Vagal tumours are rare, but understanding how the vagus nerve works helps make sense of the symptoms they produce. For the complete guide to vagal anatomy and function, get the Vagus Nerve & Me eBook.




